JPH0511788B2 - - Google Patents
Info
- Publication number
- JPH0511788B2 JPH0511788B2 JP60233348A JP23334885A JPH0511788B2 JP H0511788 B2 JPH0511788 B2 JP H0511788B2 JP 60233348 A JP60233348 A JP 60233348A JP 23334885 A JP23334885 A JP 23334885A JP H0511788 B2 JPH0511788 B2 JP H0511788B2
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- concentration
- difference
- absorbance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000427 antigen Substances 0.000 claims description 88
- 102000036639 antigens Human genes 0.000 claims description 88
- 108091007433 antigens Proteins 0.000 claims description 88
- 238000002835 absorbance Methods 0.000 claims description 44
- 239000002245 particle Substances 0.000 claims description 35
- 238000006243 chemical reaction Methods 0.000 claims description 24
- 238000002834 transmittance Methods 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 20
- 230000008859 change Effects 0.000 claims description 9
- 230000003100 immobilizing effect Effects 0.000 claims description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 45
- 102100032752 C-reactive protein Human genes 0.000 description 45
- 239000012085 test solution Substances 0.000 description 37
- 238000012360 testing method Methods 0.000 description 29
- 239000007788 liquid Substances 0.000 description 26
- 238000005259 measurement Methods 0.000 description 22
- 239000000872 buffer Substances 0.000 description 12
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 238000000691 measurement method Methods 0.000 description 8
- 239000000376 reactant Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 230000002776 aggregation Effects 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 229940027941 immunoglobulin g Drugs 0.000 description 5
- 239000004816 latex Substances 0.000 description 5
- 229920000126 latex Polymers 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- 238000011546 CRP measurement Methods 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 3
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 3
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 3
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 229920000620 organic polymer Polymers 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 229920003048 styrene butadiene rubber Polymers 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229910052809 inorganic oxide Inorganic materials 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000005375 photometry Methods 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 230000005653 Brownian motion process Effects 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- -1 antinuclear factor Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000005537 brownian motion Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001268 chyle Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000007720 emulsion polymerization reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000010954 inorganic particle Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920002454 poly(glycidyl methacrylate) polymer Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000011164 primary particle Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- CIJQGPVMMRXSQW-UHFFFAOYSA-M sodium;2-aminoacetic acid;hydroxide Chemical compound O.[Na+].NCC([O-])=O CIJQGPVMMRXSQW-UHFFFAOYSA-M 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 108010075210 streptolysin O Proteins 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
Landscapes
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP23334885A JPS6293664A (ja) | 1985-10-21 | 1985-10-21 | 抗原又は抗体濃度の測定方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP23334885A JPS6293664A (ja) | 1985-10-21 | 1985-10-21 | 抗原又は抗体濃度の測定方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6293664A JPS6293664A (ja) | 1987-04-30 |
| JPH0511788B2 true JPH0511788B2 (fi) | 1993-02-16 |
Family
ID=16953738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP23334885A Granted JPS6293664A (ja) | 1985-10-21 | 1985-10-21 | 抗原又は抗体濃度の測定方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6293664A (fi) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994010551A1 (en) * | 1992-10-30 | 1994-05-11 | Sarasep, Inc. | Method for particulate reagent sample treatment |
| EP2259069B1 (en) * | 2008-03-31 | 2018-09-12 | Sysmex Corporation | Blood coagulation analyzer and method of analyzing blood coagulation |
| JP5312834B2 (ja) * | 2008-03-31 | 2013-10-09 | シスメックス株式会社 | 血液凝固分析装置、血液凝固分析方法、及び、コンピュータプログラム |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59171863A (ja) * | 1983-03-18 | 1984-09-28 | Mitsubishi Chem Ind Ltd | 抗原抗体反応の測定方法 |
-
1985
- 1985-10-21 JP JP23334885A patent/JPS6293664A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59171863A (ja) * | 1983-03-18 | 1984-09-28 | Mitsubishi Chem Ind Ltd | 抗原抗体反応の測定方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6293664A (ja) | 1987-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6243138B2 (fi) | ||
| EP0724156A1 (en) | Kit for immunologically assaying biological substance and assay process | |
| CA2023803C (en) | Method for measuring an immunologically active material and apparatus suitable for practicing said method | |
| AU2002313319B2 (en) | Carrier particle latex for assay reagent and assay reagent | |
| EP0263731A1 (en) | Method for measuring antigen-antibody reactions | |
| JPS61265571A (ja) | 異なる比重をもつ相補的粒子を用いる遠心の場におけるイムノアツセイ法 | |
| JP4086266B2 (ja) | 免疫測定方法 | |
| JPH0511788B2 (fi) | ||
| JP3005400B2 (ja) | 抗原または抗体濃度の測定方法 | |
| JPS6293663A (ja) | 抗原又は抗体濃度の測定方法 | |
| JP2004325414A (ja) | 免疫測定方法及び免疫測定キット | |
| EP0439611B1 (en) | Method for assaying immunologically active substance and reagent therefor | |
| CN111239403B (zh) | 一种β2微球蛋白胶乳增强免疫比浊试剂盒及应用 | |
| JP2001074742A (ja) | ラテックス免疫比濁法および測定キット | |
| JPH0614049B2 (ja) | 抗原又は抗体濃度の測定方法 | |
| JPH03233358A (ja) | 抗原または抗体の高感度測定法 | |
| JP3328053B2 (ja) | 免疫凝集反応による抗体又は抗原の濃度定量法 | |
| JPH0682128B2 (ja) | ラテツクス試薬 | |
| JP2575148B2 (ja) | 試 薬 | |
| JP2001050963A (ja) | 免疫学的凝集反応試薬 | |
| JP2704760B2 (ja) | 凝集抗体 | |
| JP2004117068A (ja) | 免疫測定試薬および免疫測定方法 | |
| JPH07111434B2 (ja) | 抗体又は抗原を固定化した不溶性担体粒子の製造方法 | |
| JPH0862214A (ja) | 生体内物質の測定方法 | |
| JPH0814581B2 (ja) | 抗原又は抗体の定量法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |